Safety and Efficacy of CRD007 in Adult Asthma Subjects
Status:
Completed
Trial end date:
2017-02-24
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomised, placebo-controlled, parallel group, Phase 2 trial
evaluating CRD007 administered orally b.i.d for 14 weeks for the treatment of asthma. CRD007
will be given as add on to a background of commonly used controller medication, i.e. inhaled
corticosteroid (ICS) with or without long-acting beta2-agonist (LABA). By gradually reducing
the background controller medication, the efficacy and safety of CRD007 will be evaluated on
top of several dose levels of this medication.